Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar i disorder (BALANCE): A randomised open-label trial
Geddes JR., Goodwin GM., Rendell J., Morriss R., Alder N., Juszczak E., Azorin JM., Cipriani A., Ostacher MJ., Lewis S., Attenburrow MJ., Carter B., Hainsworth J., Healey C., Stevens W., Van Gucht ED., Young H., Davies C., Peto R., Barnes TRE., Curtis V., Johnson T., Marven M., Arif M., Bruce J., Drybala G., Hayden E., Jhingan HP., Marudkar M., Hillier R., Barrett S., Lidder JS., McCartney M., Middleton H., Ononye F., Solanki RD., Agell I., Anjum R., Hunt N., Jones P., Ramana R., Chase J., Ayuba L., Macmillan I., Michael A., Frangou S., Gijsman H., Parker E., Phillips M., Behr G., Tyrer P., Conway A., Ferrier N., Oakley T., Tower N., Young A., Chitty R., Littlejohns C., Suri A., Iqbal M., Zikis P., Anderson I., O'Driscoll D., Robbins N., Ash G., Chaudhry I., Duddu V., Reed P., Van Wyk S., Vohra A., Zingela Z., Mahmood T., Diedricks H., Faizal MA., McCarthy J., Briess D., Ceccherini-Nelli A., Clifford E., Croos R., Davis JDR., De Silva L., Eranti S., Mahmoud R., Maurya A., Partovi-Tabar P., Rahimi Y., Tuson J., Greening J., Campbell C., Grewal JS., Kumar A., Schultewolter D., Baldwin D., Best N., Herod N., Polson R., Shawcross C., Khan U., Almoshmosh N., El-Adl M.
Background Lithium carbonate and valproate semisodium are both recommended as monotherapy for prevention of relapse in bipolar disorder, but are not individually fully effective in many patients. If combination therapy with both agents is better than monotherapy, many relapses and consequent disability could be avoided. We aimed to establish whether lithium plus valproate was better than monotherapy with either drug alone for relapse prevention in bipolar I disorder. Methods 330 patients aged 16 years and older with bipolar I disorder from 41 sites in the UK, France, USA, and Italy were randomly allocated to open-label lithium monotherapy (plasma concentration 0.4-1.0 mmol/L, n=110), valproate monotherapy (750-1250 mg, n=110), or both agents in combination (n=110), after an active run-in of 4-8 weeks on the combination. Randomisation was by computer program, and investigators and participants were informed of treatment allocation. All outcome events were considered by the trial management team, who were masked to treatment assignment. Participants were followed up for up to 24 months. The primary outcome was initiation of new intervention for an emergent mood episode, which was compared between groups by Cox regression. Analysis was by intention to treat. This study is registered, number ISRCTN 55261332. Findings 59 (54%) of 110 people in the combination therapy group, 65 (59%) of 110 in the lithium group, and 76 (69%) of 110 in the valproate group had a primary outcome event during follow-up. Hazard ratios for the primary outcome were 0-59 (95% CI 0.42-0.83, p=0.0023) for combination therapy versus valproate, 0.82 (0.58-1.17, p=0.27) for combination therapy versus lithium, and 0.71 (0.51-1.00, p=0.0472) for lithium versus valproate. 16 participants had serious adverse events after randomisation: seven receiving valproate monotherapy (three deaths); five lithium monotherapy (two deaths); and four combination therapy (one death). Interpretation For people with bipolar I disorder, for whom long-term therapy is clinically indicated, both combination therapy with lithium plus valproate and lithium monotherapy are more likely to prevent relapse than is valproate monotherapy. This benefit seems to be irrespective of baseline severity of illness and is maintained for up to 2 years. BALANCE could neither reliably confirm nor refute a benefit of combination therapy compared with lithium monotherapy.